Español 
English
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Artículos Relacionados
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
-
UDIBI
Fecha de publicación: 20 Septiembre 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable...
-
UDIBI
Fecha de publicación: Enero 2019Valproic acid promotes a decrease in mycobacterial survival by enhancing nitric oxide production in macrophages...
-
UDIBI
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. VER MÁS
-
-
UDIBI
SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library VER MÁS
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
-
UDIBI
Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. VER MÁS
